Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Leitzel

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
The Oncologist|August 19, 2016
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal MetastasesArlindo R Ferreira, Irina Alho, Ning Shan, et al.
Cancer|April 2, 2011
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapyAllan Lipton, Kim Leitzel, Suhail M Ali, et al.
Clinical Chemistry|July 27, 2002
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancerSuhail M Ali, Kim Leitzel, Vernon M Chinchilli, et al.
Cancer|July 28, 2010
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumabAllan Lipton, Wolfgang J Köstler, Kim Leitzel, et al.
Plos One|January 10, 2013
Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapyAhmed A Alkhateeb, Kim Leitzel, Suhail M Ali, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 7, 2013
Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasisCharity L Washam, Stephanie D Byrum, Kim Leitzel, et al.
Cancer|October 19, 2006
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancerChristopher Souder, Kim Leitzel, Suhail M Ali, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 4, 2017
PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and LifespanArchana Kamalakar, Charity L Washam, Nisreen S Akel, et al.
Leukemia Research|September 29, 2009
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agentsEvangelos Terpos, Meletios A Dimopoulos, Vikas Shrivastava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancerAllan Lipton, Kim Leitzel, Hilary A Chaudri-Ross, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The Oncologist|August 19, 2016
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal MetastasesArlindo R Ferreira, Irina Alho, Ning Shan, et al.
Cancer|April 2, 2011
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapyAllan Lipton, Kim Leitzel, Suhail M Ali, et al.
Clinical Chemistry|July 27, 2002
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancerSuhail M Ali, Kim Leitzel, Vernon M Chinchilli, et al.
Cancer|July 28, 2010
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumabAllan Lipton, Wolfgang J Köstler, Kim Leitzel, et al.
Plos One|January 10, 2013
Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapyAhmed A Alkhateeb, Kim Leitzel, Suhail M Ali, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 7, 2013
Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasisCharity L Washam, Stephanie D Byrum, Kim Leitzel, et al.
Cancer|October 19, 2006
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancerChristopher Souder, Kim Leitzel, Suhail M Ali, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 4, 2017
PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and LifespanArchana Kamalakar, Charity L Washam, Nisreen S Akel, et al.
Leukemia Research|September 29, 2009
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agentsEvangelos Terpos, Meletios A Dimopoulos, Vikas Shrivastava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancerAllan Lipton, Kim Leitzel, Hilary A Chaudri-Ross, et al.
Pageof 4